{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T17:05:21Z","timestamp":1782320721404,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T00:00:00Z","timestamp":1590796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T00:00:00Z","timestamp":1590796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","award":["2016-635"],"award-info":[{"award-number":["2016-635"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s00262-020-02617-5","type":"journal-article","created":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T18:02:42Z","timestamp":1590861762000},"page":"2223-2232","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Differences in PD-1 expression on CD8+ T-cells in chronic myeloid leukemia patients according to disease phase and TKI medication"],"prefix":"10.1007","volume":"69","author":[{"given":"Min Young","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4396-8348","authenticated-orcid":false,"given":"Chan-Jeoung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Uk","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunkyoung","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongsoo","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Ahn","family":"Seol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eul-Ju","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Ji","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je-Hwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,30]]},"reference":[{"key":"2617_CR1","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","volume":"224","author":"BT Fife","year":"2008","unstructured":"Fife BT, Bluestone JA (2008) Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 224:166\u2013182","journal-title":"Immunol Rev"},{"key":"2617_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","volume":"27","author":"MJ Butte","year":"2007","unstructured":"Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ (2007) Programmed death-1 ligand 1 interacts specifically with the B7\u20131 costimulatory molecule to inhibit T cell responses. Immunity 27:111\u2013122","journal-title":"Immunity"},{"key":"2617_CR3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","volume":"236","author":"LM Francisco","year":"2010","unstructured":"Francisco LM, Sage PT, Sharpe AH (2010) The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236:219\u2013242","journal-title":"Immunol Rev"},{"key":"2617_CR4","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677\u2013704","journal-title":"Annu Rev Immunol"},{"key":"2617_CR5","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel SP, Kurzrock R (2015) PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14:847\u2013856","journal-title":"Mol Cancer Ther"},{"key":"2617_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3389\/fimmu.2017.00469","volume":"8","author":"A Hughes","year":"2017","unstructured":"Hughes A, Yong AS (2017) Immune effector recovery in chronic myeloid leukemia and treatment-free remission. Front Immunol 8:469","journal-title":"Front Immunol"},{"key":"2617_CR7","doi-asserted-by":"publisher","first-page":"e55818","DOI":"10.1371\/journal.pone.0055818","volume":"8","author":"L Christiansson","year":"2013","unstructured":"Christiansson L, S\u00f6derlund S, Svensson E, Mustjoki S, Bengtsson M, Simonsson B, Olsson-Str\u00f6mberg U, Loskog AS (2013) Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1\/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. PLoS ONE 8:e55818","journal-title":"PLoS ONE"},{"key":"2617_CR8","doi-asserted-by":"crossref","unstructured":"Hughes A, Clarson J, Tang C, Vidovic L, White DL, Hughes TP, Yong AS (2017) CML patients with deep molecular responses to TKI have restored immune effectors, decreased PD-1 and immune suppressors. Blood:blood-2016\u20132010\u2013745992","DOI":"10.1182\/blood-2016-10-745992"},{"key":"2617_CR9","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.6004\/jnccn.2016.0162","volume":"14","author":"A Pallera","year":"2016","unstructured":"Pallera A, Altman JK, Berman E, Abboud CN, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hagelstrom RT, Hobbs G (2016) NCCN guidelines insights: chronic myeloid leukemia, version 1.2017. J Natl Compr Cancer Netw 14:1505\u20131512","journal-title":"J Natl Compr Cancer Netw"},{"key":"2617_CR10","unstructured":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (2017). Media centre\u2014IARC news"},{"key":"2617_CR11","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1586\/1744666X.2015.1019474","volume":"11","author":"V Vonka","year":"2015","unstructured":"Vonka V, Petr\u00e1\u010dkov\u00e1 M (2015) Immunology of chronic myeloid leukemia: current concepts and future goals. Expert Rev Clin Immunol 11:511\u2013522","journal-title":"Expert Rev Clin Immunol"},{"key":"2617_CR12","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1038\/leu.2008.161","volume":"22","author":"AS Yong","year":"2008","unstructured":"Yong AS, Keyvanfar K, Eniafe R, Savani BN, Rezvani K, Sloand EM, Goldman JM, Barrett AJ (2008) Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy. Leukemia 22:1721","journal-title":"Leukemia"},{"key":"2617_CR13","doi-asserted-by":"publisher","first-page":"vii72","DOI":"10.1093\/annonc\/mds228","volume":"23","author":"M Baccarani","year":"2012","unstructured":"Baccarani M, Pileri S, Steegmann J-L, Muller M, Soverini S, Dreyling M, Group EGW (2012) Chronic myeloid leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23:vii72\u2013vii77","journal-title":"Ann Oncol"},{"key":"2617_CR14","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1182\/blood-2008-09-179697","volume":"114","author":"S Mumprecht","year":"2009","unstructured":"Mumprecht S, Sch\u00fcrch C, Schwaller J, Solenthaler M, Ochsenbein AF (2009) Programmed death 1 signaling on chronic myeloid leukemia\u2013specific T cells results in T-cell exhaustion and disease progression. Blood 114:1528\u20131536","journal-title":"Blood"},{"key":"2617_CR15","first-page":"17","volume":"1","author":"A Kreutzman","year":"2013","unstructured":"Kreutzman A, Porkka K, Mustjoki S (2013) Immunomodulatory effects of tyrosine kinase inhibitors. Int Trends Immun 1:17\u201328","journal-title":"Int Trends Immun"},{"key":"2617_CR16","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/nm.2438","volume":"17","author":"VP Balachandran","year":"2011","unstructured":"Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, Sorenson EC, Popow R, Ariyan C, Rossi F (2011) Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 17:1094","journal-title":"Nat Med"},{"issue":"205","key":"2617_CR17","first-page":"11","volume":"198","author":"KE Pauken","year":"2017","unstructured":"Pauken KE, Juneja V, McGuire K, LaFleur M, Kuchroo J, Sage P, Chevrier N, Freeman GJ, Sharpe AH (2017) CD8+ T cell-independent mechanisms of PD-1-mediated suppression of anti-tumor immunity in mice. Am Assoc Immnol 198(205):11","journal-title":"Am Assoc Immnol"},{"key":"2617_CR18","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1038\/leu.2011.135","volume":"25","author":"A Kreutzman","year":"2011","unstructured":"Kreutzman A, Ladell K, Koechel C, Gostick E, Ekblom M, Stenke L, Melo T, Einsele H, Porkka K, Price D (2011) Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia 25:1587","journal-title":"Leukemia"},{"key":"2617_CR19","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41375-018-0175-0","volume":"32","author":"O Br\u00fcck","year":"2018","unstructured":"Br\u00fcck O, Blom S, Dufva O, Turkki R, Chheda H, Ribeiro A, Kovanen P, Aittokallio T, Koskenvesa P, Kallioniemi O (2018) Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML. Leukemia 32:1643\u20131656","journal-title":"Leukemia"},{"key":"2617_CR20","doi-asserted-by":"publisher","first-page":"6955","DOI":"10.4049\/jimmunol.181.10.6955","volume":"181","author":"N Larmonier","year":"2008","unstructured":"Larmonier N, Janikashvili N, LaCasse CJ, Larmonier CB, Cantrell J, Situ E, Lundeen T, Bonnotte B, Katsanis E (2008) Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL\u2212 tumors. J Immunol 181:6955\u20136963","journal-title":"J Immunol"},{"key":"2617_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1365-2141.2008.07433.x","volume":"144","author":"F Fei","year":"2009","unstructured":"Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, G\u00f6tz M, D\u00f6hner H, Bunjes D, Schmitt M (2009) Dasatinib inhibits the proliferation and function of CD4+ CD25+ regulatory T cells. Br J Haematol 144:195\u2013205","journal-title":"Br J Haematol"},{"key":"2617_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1476-4598-9-22","volume":"9","author":"F Fei","year":"2010","unstructured":"Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Greiner J, G\u00f6tz M, Bunjes D, Schmitt M (2010) Effects of nilotinib on regulatory T cells: the dose matters. Mol Cancer 9:22","journal-title":"Mol Cancer"},{"key":"2617_CR23","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1097\/01.HS9.0000566240.73600.4a","volume":"3","author":"M Lee","year":"2019","unstructured":"Lee M, Park C-J, Cho Y-U, Jang S (2019) Expression levels of PD-1 on T cells in chronic myeloid leukemia: PB1936. HemaSphere 3:880\u2013881","journal-title":"HemaSphere"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02617-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02617-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02617-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T23:21:22Z","timestamp":1622330482000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02617-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,30]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["2617"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02617-5","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,30]]},"assertion":[{"value":"25 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was approved by the institutional review board of Asan Medical Center (Approval number: 20161087) and was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"No potential conflicts of interest relevant to this article were reported.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}